Skip To Main Content
Lilly
Menu closed
Lilly
    Lilly

    You are now leaving the LillyMedical website

    The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
    Click "Continue" to proceed or "Return" to return to LillyMedical.

    Neuroscience Journal Publications

    This page includes links to Lilly sponsored trials and observational research that have been published in peer reviewed journals within the last 5 years. Each section is sorted by product and may be expanded for more information. The list of publications below is limited to products that have been approved for use and may contain information about doses, delivery devices, uses, formulations and populations different from product labeling. Clinical decisions should be based on the full safety and efficacy information contained in the product's Full Prescribing Information in the provided link below.

    If you have questions about a Lilly study not listed below or would like to request an electronic copy of one of the journal publications on this page, please call 1-800-LILLYRX (1-800-545-5979). For our publication linking statement click here.

    For all other requests, please visit our Contact Lilly services.

    Amyvid® (florbetapir F18 injection)

    Full Prescribing Information

    No Publication Journals

    No Publication Journals

    No Publication Journals

    No Publication Journals

    Cymbalta® (duloxetine)

    Full Prescribing Information

    No Publication Journals

    No Publication Journals

    No Publication Journals

    No Publication Journals

    Emgality® (galcanezumab-gnlm)

    Full Prescribing Information

    No Publication Journals

    No Publication Journals

    No Publication Journals

    No Publication Journals

    Comparison of Treatment Patterns in Patients with Migraine Initiating Calcitonin Gene-Related Peptide Monoclonal Antibodies: A Retrospective Real-World US Study.
    Published Date: January 9, 2024
    Migraine-Related Stigma and Its Relationship to Disability, Interictal Burden, and Quality of Life: Results of the OVERCOME (US) Study
    Published Date: February 13, 2024
    Treatment patterns of galcanezumab versus standard of care preventive migraine medications over 24 months: a US retrospective claims study.
    Published Date: February 22, 2024
    Annual indirect costs savings in patients with episodic or chronic migraine: a post-hoc analysis of phase 3 galcanezumab clinical trials in the United States.
    Published Date: January 9, 2023
    Clinical characteristics and treatment patterns of patients with episodic cluster headache: results from the United States, United Kingdom and Germany.
    Published Date: August 24, 2023
    Treatment Patterns, Healthcare Resource Utilization, and Direct Costs Among Patients Initiating Concomitant Use of a Calcitonin Gene-Related Peptide Monoclonal Antibody (CGRP mAb) and Novel Acute Medication in the United States
    Published Date: December 18, 2023
    Diagnosis, consultation, treatment, and impact of migraine in the US: Results of the OVERCOME (US) study.
    Published Date: January 25, 2022
    Treatment patterns for calcitonin gene-related peptide monoclonal antibodies including galcanezumab versus conventional preventive treatments for migraine: a retrospective US claims study.
    Published Date: March 28, 2022
    Patient characteristics and treatment utilization among patients with migraine initiating self-injectable calcitonin gene-related peptide monoclonal antibody and novel acute medication.
    Published Date: July 12, 2022
    Healthcare Resource Utilization and Costs Associated with Treatment Among Patients Initiating Calcitonin Gene-Related Peptide Inhibitors versus Other Preventive Migraine Treatments in the US.
    Published Date: August 1, 2022
    Direct cost and healthcare resource utilization of patients with migraine before treatment initiation with calcitonin gene-related peptide monoclonal antibodies by the number of prior preventive migraine medication classes.
    Published Date: November 30, 2021
    Economic Burden and Risk Factors of Migraine Disease Progression in the US: A Retrospective Analysis of a Commercial Payer Database.
    Published Date: September 12, 2020
    A Real-World Analysis of Patient-Reported Outcomes in Patients with Migraine by Preventive Treatment Eligibility Status in the US and Europe
    Published Date: July 6, 2020

    Reyvow® (lasmiditan)

    Full Prescribing Information

    No Publication Journals

    No Publication Journals

    No Publication Journals

    No Publication Journals

    Can't find what you're looking for? Contact us for answers to your medical questions.

    • Copyright
    • Terms of Use
    • Privacy Statement
    • Consumer Health Privacy Notice
    • Accessibility Statement
    • Sitemap
       

      This site is intended for US Healthcare Professionals only.

      4.0.66 5/2025 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2025. All rights reserved.

      Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

      California Consumer Privacy Act (CCPA) Opt-Out Icon Your Privacy Choices
      Cookie Settings
      Facebook X LinkedIn
      Lilly